遗传变异与纳武利尤单抗诱导的免疫相关不良事件风险的关联。
Association between genetic variants and the risk of nivolumab-induced immune-related adverse events.
机构信息
Department of Genetics Medicine & services, National Cancer Center Hospital, Tokyo, 104-0045, Japan.
Division of Breast & Endocrine Surgery, Department of Surgery, St. Marianna University School of Medicine, Kawasaki, 216-8511, Japan.
出版信息
Pharmacogenomics. 2022 Nov;23(16):887-901. doi: 10.2217/pgs-2022-0113. Epub 2022 Oct 21.
We sought to identify the variants that could predict the risk of nivolumab-induced immune-related adverse events (irAEs) in patients with cancer. We enrolled 622 Japanese patients and carried out a genome-wide association study. The associations for 507 single nucleotide polymorphisms (SNPs) showing p < 0.001 were further investigated using an independent cohort. In the combined analysis, possible associations were found for a total of 90 SNPs. Although no SNPs were identified to be significantly associated with nivolumab-induced irAEs, the SNP most strongly associated with nivolumab-induced irAEs was rs469490. This study is an important hypothesis-generating study to guide future studies in larger and/or other ethnic cohorts.
我们试图确定能够预测癌症患者接受nivolumab 治疗后发生免疫相关不良事件（irAEs）风险的变异。我们纳入了 622 名日本患者，并进行了全基因组关联研究。使用独立队列进一步研究了 507 个单核苷酸多态性（SNP），这些 SNP 的 p 值均<0.001。在联合分析中，总共发现了 90 个可能与 nivolumab 诱导的 irAEs 相关的 SNP。虽然没有 SNP 被确定与 nivolumab 诱导的 irAEs 有显著相关性，但与 nivolumab 诱导的 irAEs 相关性最强的 SNP 是 rs469490。这项研究是一项重要的假说生成研究，为未来在更大规模和/或其他种族队列中开展研究提供了指导。
Zotero 插件